| Ytd | -67.82% | |
| 1y | -46.78% |
| Open | 3.69 | Prev Close | 3.66 | Low | 3.61 | High | 3.75 | Mkt Cap | 242.55M |
| Vol | 1.61M | Avg Vol | 2.25M | EPS | -1.15 | P/E | N/A | Forward P/E | -3.84 |
| Beta | 2.23 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-27 | 50-d Avg | 5.56 | 200-d Avg | 8.46 | 1yr Est | 5.29 |
FULC News
On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restru
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins
Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade T
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and
Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweig
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outpe
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC,
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. T
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA